Loading
Latest filing published 19 Feb 2025 for Arbutus Biopharma Corporation.
No signal scores available.
David Cummins Hastings discloses dealings in Arbutus Biopharma Corporation to SEDI. The record holds 3 filings, for trades running from 11 June 2018 to 14 February 2025.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Most recently, on 19 February 2025, the filings show a share grant in Arbutus Biopharma Corporation. Filings reach the SEDI feed a median of 5 days after the trade. That lag is the time during which only the insider knows about the trade. This summary is built from SEDI disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations